All News
More severe COVID-19 outcomes in African American, Hispanic individuals with SLE
A study from ACR21 convergence discussing data from the Global Rheumatology Alliance (GRA) describes the association between race/ethnicity on COVID-19 outcomes specifically in lupus patients.
Read Article
Racial/ethnic disparity in U.S. lupus nephritis mortality
At #ACR21, the plenary session included an analysis of deaths from SLE throughout the US comparing 1999 to 2019 (Abstract #0454).
Read Article
ACR21 Best Abstracts - Day 4
On the last day of ACR21 Annual Meeting, the RheumNow faculty selected these 15 as their favorite reports.
Read Article
Predictors of Remission and Low Disease Activity in SLE
A treat-to-target strategy has been shown to improve clinical outcomes in patients with rheumatic diseases like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis including systemic lupus erythematosus. The goal of treatment in SLE is aimed at remission or low disease activit
Read Article
ICYMI: Type 1 and Type II Lupus — Patient Perspectives: Dr. Mehta ( @bella_mehta) interviews Dr. Clowse about abstract #1277 presented at the #ACR21 annual meeting
https://t.co/2w1Lwwhplf https://t.co/4sJR6DG0q0
Links:
Dr. John Cush RheumNow ( View Tweet)
Frailty in Lupus: Dr. Sheila Reyes ( @RHEUMarampa) reviews abstract #0869 presented at the #ACR21 annual meeting.
https://t.co/5jR74VQBeG https://t.co/AJIhR5Waip
Links:
Dr. John Cush RheumNow ( View Tweet)
Vitamin D and Hydroxychloroquine Studies: Dr. Michelle Petri discussed studies regarding Vitamin D supplementation and as well as data on hydroxychloroquine that was presented Saturday at the #ACR21 annual meeting.
https://t.co/CU8wFVYhNg
Links:
Dr. John Cush RheumNow ( View Tweet)
Hydroxychloroquine Levels in Type I and 2 Lupus: Bella Mehta ( @bella_mehta) interviews Dr. Megan Clowse about abstract #0877, presented at the #ACR21 annual meeting.
https://t.co/L62iO8J9QF https://t.co/Oy58jbPPts
Links:
Dr. John Cush RheumNow ( View Tweet)
Treat to Target in SLE: Dr. Yuzaiful Yusof ( @Yuz6Yusof ) reviews abstract #0865 presented at the #ACR21 annual meeting.
https://t.co/THX4nLWCaR https://t.co/951HAdkONi
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI:
Watch: Lupus Updates: Dr. Michelle Petri
Dr. Michelle Petri offers perspective and insight into lupus related data presented Saturday at the #ACR21 annual meeting.
https://t.co/nluRreQPT1 https://t.co/fzm1RW6Rpy
Links:
Dr. John Cush RheumNow ( View Tweet)
Lupus Day 2 Highlights: Drs Dao , Mehta, Yusof, Pope, Reyes and Castillo review lupus-related information and data presented during day 2 of the #ACR21 annual
meeting.
https://t.co/QX6Ay77FKo
@KDAO2011 @bella_mehta @Yuz6Yusof @Janetbirdope @RHEUMarampa @_Castillo_Pedro https://t.co/ldAHqXsi0G
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR21 The Great Debate: Belimumab vs Voclosporin as Add-On Therapy in #LupusNephritis | Dr. Petri & Dr. Rovin
Audience Vote 🗳: What would you add to mycophenolate first?
Belimumab 71%, Voclosporin 29%
#ACRAmbassador @ACRheum
Summary of Pros & Cons of Each⬇️ https://t.co/OtLxs8IYr9
Mithu Maheswaranathan, MD MithuRheum ( View Tweet)
#ACR21 TM26. Familial chilblains lupus seen in genetic mutation in Three Prime Repair Exonuclease 1 (TREX1). Suspected due to onset in infancy.
@Rheumnow https://t.co/ZryOpeoJT8 https://t.co/LqZqoGDAL2
Links:
Eric Dein ericdeinmd ( View Tweet)
Update on Safety, Effectiveness of SARS-CoV-2 vaccines in SLE from Dr. Yuz Yusof ( @Yuz6Yusof)
It's almost a year since the Pfizer-BioNTech SARS-CoV-2 vaccine has been made available by the FDA under EUA. But is the vaccine safe for people with lupus?
https://t.co/i3HeCvS6El https://t.co/Tn0nWKrK4T
Links:
Dr. John Cush RheumNow ( View Tweet)
GRA @rheum_covid data presented by @mugartegil. African-American and Hispanic individuals with SLE have MUCH worse COVID-19 outcomes. Likely related socioeconomic and health disparities. Abstr#1933 #ACR21 @RheumNow https://t.co/YUoOeIxN7O
Richard Conway RichardPAConway ( View Tweet)
#ACR21 #Abstr1909 📢We need to stress the importance of hydroxychloroquine adherence to our patients. Adherence (>90% of the time) reduced premature CVD mortality by 52% in #rheumatoidarthritis and #lupus. The study didn’t adjust for smoking @RheumNow https://t.co/D9pGqwWhje https://t.co/R6r3cSexUB
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
HCQ adherence (>90%) associated with 52% reduced cardiovascular mortality in RA and SLE. Seen for MI, stroke, not VTE. Abstr#1909 #ACR21 @RheumNow https://t.co/5UncmqZVNp
Richard Conway RichardPAConway ( View Tweet)
Claims data looked at 21,114 #RA & #SLE pts - 4.3% had CV Death. The risk of CVD was worse w/ HCQ nonadherence (HR 1.08; 0.91-1.31) and better w/ HCQ adherence (HR 0.51;0.42-.66) HCQ nonadherence shows higher CV mortality #ACR21 Abst# 1909 https://t.co/di1mBliMN6
Dr. John Cush RheumNow ( View Tweet)
#ACR21 TM18
⭐️Spontaneous coronary artery dissection (SCAD) of LAD
▶️ +Sicca, Photosensitivity, malar erythema, alopecia, oral ulcers, arthralgias
▶️ ANA negative, dsDNA HIGH
Rare case of ANA negative SLE with odd presentation!
https://t.co/jfmVtZ4iOV @RheumNow https://t.co/pMHcColeUn
Links:
Eric Dein ericdeinmd ( View Tweet)
60% don’t use pneumocystis prophylaxis #PJP in #lupus #SLE @RheumNow #ACR21 https://t.co/AVf97xJhtL
Janet Pope Janetbirdope ( View Tweet)
